The group has over 20 years of experience in clinical and translational research on Alzheimer’s disease. The main scientific interest is the use of neuroimaging techniques and other biomarkers in persons with or at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences, ICT, and technology are uptaken and translated for use into a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. Specific topics of investigation are: the clinical use of imaging and fluid biomarkers; in vivo neurobiology of Alzheimer’s disease; the clinical use of innovative PET ligands; harmonisation of imaging markers for clinical use; development of innovative image analysis environments based on advanced ICT technology.
Respectful Caring for the Agitated Elderly (ReCAGE): A Multicentre, Prospective, Observational Study to Evaluate the Effectiveness of Special Care Units for People with Dementia.
Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study.
Harmonization of brain PET images in multi-center PET studies using Hoffman phantom scan.
Impact of simulated reduced injected dose on the assessment of amyloid PET scans.
Département de psychiatrie